Biblio
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024.
. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024.
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024.
. Comparison of Pretransplant Prediction Models for Non-Relapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023;13(1):3.
. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023.
. . .
Treatment of Myelofibrosis: A Moving Target. Cancer J. 2016;22(1):51-61.
. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015;1(1):97-105.
. Myeloproliferative Neoplasms: A Decade of Discoveries and Treatment Advances. Am J Hematol. 2015.
.